RIFAMPIN

N/A

Manufactured by Sanofi-Aventis U.S. LLC

22,393 FDA adverse event reports analyzed

Last updated: 2026-04-14

About RIFAMPIN

RIFAMPIN is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Sanofi-Aventis U.S. LLC. The most commonly reported adverse reactions for RIFAMPIN include DRUG INEFFECTIVE, OFF LABEL USE, DRUG INTERACTION, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS, NAUSEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for RIFAMPIN.

Top Adverse Reactions

DRUG INEFFECTIVE1,468 reports
OFF LABEL USE1,107 reports
DRUG INTERACTION970 reports
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS727 reports
NAUSEA630 reports
CONDITION AGGRAVATED550 reports
PYREXIA541 reports
PRODUCT USE IN UNAPPROVED INDICATION533 reports
VOMITING445 reports
DRUG RESISTANCE437 reports
ACUTE KIDNEY INJURY396 reports
DRUG INTOLERANCE391 reports
DYSPNOEA380 reports
DIARRHOEA378 reports
RASH378 reports
PARADOXICAL DRUG REACTION363 reports
COUGH350 reports
FATIGUE336 reports
DRUG INDUCED LIVER INJURY325 reports
TREATMENT FAILURE308 reports
PRURITUS299 reports
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION278 reports
THROMBOCYTOPENIA262 reports
MYCOBACTERIUM AVIUM COMPLEX INFECTION249 reports
TUBERCULOSIS243 reports
HEADACHE240 reports
PAIN240 reports
WEIGHT DECREASED235 reports
NEUTROPENIA224 reports
ARTHRALGIA218 reports
ANAEMIA212 reports
PNEUMONIA211 reports
ASTHENIA208 reports
DRUG HYPERSENSITIVITY205 reports
IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME195 reports
ABDOMINAL PAIN194 reports
DECREASED APPETITE194 reports
DIZZINESS194 reports
EOSINOPHILIA190 reports
DEATH185 reports
MALAISE178 reports
HEPATOTOXICITY175 reports
RENAL FAILURE174 reports
HEPATIC CYTOLYSIS163 reports
RASH MACULO PAPULAR163 reports
TOXICITY TO VARIOUS AGENTS161 reports
DISEASE PROGRESSION151 reports
RENAL IMPAIRMENT143 reports
TUBULOINTERSTITIAL NEPHRITIS140 reports
PRODUCTIVE COUGH137 reports
HYPERTENSION134 reports
PANCYTOPENIA134 reports
GASTROINTESTINAL DISORDER133 reports
HYPOTENSION133 reports
HIDRADENITIS126 reports
GENERAL PHYSICAL HEALTH DETERIORATION125 reports
DRUG LEVEL DECREASED124 reports
ALANINE AMINOTRANSFERASE INCREASED119 reports
MYALGIA116 reports
NEUROPATHY PERIPHERAL116 reports
SEPSIS116 reports
THERAPY NON RESPONDER116 reports
MULTIPLE ORGAN DYSFUNCTION SYNDROME115 reports
ASPARTATE AMINOTRANSFERASE INCREASED114 reports
STAPHYLOCOCCAL INFECTION114 reports
ANXIETY113 reports
INSOMNIA113 reports
RESPIRATORY FAILURE112 reports
URTICARIA111 reports
HEPATITIS109 reports
LEUKOPENIA109 reports
ACUTE HEPATIC FAILURE107 reports
CONFUSIONAL STATE106 reports
HYPERSENSITIVITY105 reports
PRODUCT DOSE OMISSION ISSUE105 reports
CHILLS104 reports
DISSEMINATED TUBERCULOSIS104 reports
ABDOMINAL DISCOMFORT103 reports
ERYTHEMA103 reports
ABDOMINAL PAIN UPPER102 reports
HAEMOPTYSIS101 reports
JAUNDICE101 reports
VISUAL IMPAIRMENT101 reports
INFECTION99 reports
CHOLESTASIS96 reports
IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED TUBERCULOSIS95 reports
TREATMENT NONCOMPLIANCE95 reports
BACK PAIN94 reports
EXPOSURE DURING PREGNANCY94 reports
LYMPHADENOPATHY94 reports
PATHOGEN RESISTANCE94 reports
HEPATIC FUNCTION ABNORMAL93 reports
PANCREATITIS93 reports
TRANSAMINASES INCREASED92 reports
PULMONARY TUBERCULOSIS91 reports
GAIT DISTURBANCE90 reports
COVID 1989 reports
DYSPHONIA89 reports
OEDEMA PERIPHERAL89 reports
CHEST PAIN88 reports

Report Outcomes

Out of 13,445 classified reports for RIFAMPIN:

Serious 83.5%Non-Serious 16.5%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Male6,092 (50.2%)
Female6,022 (49.6%)
Unknown32 (0.3%)

Reports by Age

Age 65240 reports
Age 71220 reports
Age 69194 reports
Age 74192 reports
Age 77184 reports
Age 68182 reports
Age 70182 reports
Age 72182 reports
Age 58178 reports
Age 64178 reports
Age 62176 reports
Age 75176 reports
Age 73171 reports
Age 57170 reports
Age 67170 reports
Age 61168 reports
Age 37159 reports
Age 55153 reports
Age 60153 reports
Age 66153 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with RIFAMPIN?

This profile reflects 22,393 FDA FAERS reports that mention RIFAMPIN. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for RIFAMPIN?

Frequently reported terms in FAERS include DRUG INEFFECTIVE, OFF LABEL USE, DRUG INTERACTION, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS, NAUSEA, CONDITION AGGRAVATED. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures RIFAMPIN?

Labeling and FAERS entries often list Sanofi-Aventis U.S. LLC in connection with RIFAMPIN. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.